Understanding GRIA4: A Protein Involved in Neurotransmitter System

Target Name: GRIA4

NCBI ID: G2893

GRIA4

Understanding GRIA4: A Protein Involved in Neurotransmitter System

Glutamate receptor ionotrophic AMPA-4 (GRIA4) is a protein that plays a crucial role in the neurotransmitter system. It is a type of ionotropic receptor that is responsible for regulating the flow of glutamate ions into the cell. Glutamate is a neurotransmitter that is involved in various functions, including learning and memory, synaptic plasticity, and mood regulation.

GRIA4 is a transmembrane protein that is located in the postsynaptic terminal of neurons. It consists of four subunits that are held together by ionic bonds. The subunits are composed of an extracellular region, a transmembrane region, and an intracellular region. The GRIA4 subunits are known to have a unique structure that allows them to interact with other proteins.

GRIA4 is involved in the regulation of many different processes in the brain, including neurotransmitter release, synaptic plasticity, and learning. It is thought to play a key role in the regulation of long-term potentiation (LTP), which is a critical component of synaptic plasticity.

GRIA4 is also involved in the regulation of short-term potentiation (STP), which is a critical component of learning and memory. It is thought to play a key role in the regulation of the strength of synaptic plasticity, which is the ability of the brain to change its response to different stimuli.

GRIA4 is also involved in the regulation of the release of neurotransmitters, including dopamine and glutamate. It is thought to play a key role in the regulation of neurotransmitter release, and may be involved in the development of neurodegenerative diseases.

GRIA4 is a potential drug target for several reasons. Firstly, it is a protein that is involved in many important functions in the brain, making it an attractive target for drug development. Secondly, its structure allows it to interact with other proteins, which makes it more difficult to target. This makes it an ideal target for small molecules that can inhibit its activity without affecting its structure.

GRIA4 is also a good biomarker for several reasons. Firstly, it is a protein that is involved in many different processes in the brain, which makes it an attractive target for biomarker development. Secondly, its expression is often increased in conditions that are associated with neurodegenerative diseases, which makes it an attractive target for diagnostic tools.

Conclusion

In conclusion, GRIA4 is a protein that plays a crucial role in the neurotransmitter system. Its unique structure and involvement in many important functions in the brain make it an attractive target for drug development and biomarker development. Further research is needed to fully understand the role of GRIA4 in the regulation of neurotransmitter release and its potential as a drug target and biomarker.

Protein Name: Glutamate Ionotropic Receptor AMPA Type Subunit 4

Functions: Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. In the presence of CACNG4 or CACNG7 or CACNG8, shows resensitization which is characterized by a delayed accumulation of current flux upon continued application of glutamate

The "GRIA4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GRIA4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets